Literature DB >> 11374791

Effects of an inhibitor of tripeptidyl peptidase II (Ala-Ala-Phe-chloromethylketone) and its combination with an inhibitor of the chymotrypsin-like activity of the proteasome (PSI) on apoptosis, cell cycle and proteasome activity in U937 cells.

M Bury1, I Młynarczuk, E Pleban, G Hoser, J Kawiak, C Wójcik.   

Abstract

AAF-AMC is not a specific TPP II substrate, since it is also hydrolyzed by purified proteasomes. Moreover, AAF-cmk, claimed to be a specific TPP II inhibitor, also inhibits the chymotrypsin-like activity of the proteasome. While AAF-cmk itself is mildly cytostatic to U-937 cells and induces cell cycle block in G1, its combination with PSI does not induce an increase in the cytostatic/cytotoxic effects. This suggests that TPP II is possibly less important for cell metabolism than it was previously believed and it is less probable that it can be able to fully compensate for the loss of the proteasome function.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11374791

Source DB:  PubMed          Journal:  Folia Histochem Cytobiol        ISSN: 0239-8508            Impact factor:   1.698


  3 in total

1.  Proteasomal chymotrypsin-like peptidase activity is required for essential functions of human monocyte-derived dendritic cells.

Authors:  Cord Naujokat; Carsten Berges; Alexandra Höh; Hubert Wieczorek; Dominik Fuchs; Jörg Ovens; Marion Miltz; Mahmoud Sadeghi; Gerhard Opelz; Volker Daniel
Journal:  Immunology       Date:  2006-11-03       Impact factor: 7.397

2.  Killing of macrophages by anthrax lethal toxin: involvement of the N-end rule pathway.

Authors:  Katherine E Wickliffe; Stephen H Leppla; Mahtab Moayeri
Journal:  Cell Microbiol       Date:  2008-02-05       Impact factor: 3.715

Review 3.  The ubiquitin-proteasome system as a drug target in cerebrovascular disease: therapeutic potential of proteasome inhibitors.

Authors:  Mario Di Napoli; BethAnn McLaughlin
Journal:  Curr Opin Investig Drugs       Date:  2005-07
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.